Dr. Basem William, MD
Claim this profileOhioHealth Research Institute
Studies Lymphoma
Studies Acute Myeloid Leukemia
6 reported clinical trials
7 drugs studied
Area of expertise
1Lymphoma
Stage IV
2Acute Myeloid Leukemia
HLA-A positive
HLA-A negative
HLA positive
Affiliated Hospitals
Clinical Trials Basem William, MD is currently running
AB-101 + Immunotherapy
for Non-Hodgkin's Lymphoma
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.
Recruiting1 award Phase 1 & 24 criteria
Selinexor + Ruxolitinib
for Myelofibrosis
This is a global, multicenter Phase 1/3 study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended dose (RD) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). In Phase 3, JAKi treatment-naïve MF participants are enrolled in 2:1 ratio to receive the combination therapy of selinexor + ruxolitinib or the combination of placebo + ruxolitinib.
Recruiting1 award Phase 320 criteria
More about Basem William, MD
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Basem William, MD has experience with
- NEXI-001 T Cell Product
- Ibrutinib
- AB-101
- Rituximab
- ASTX660
- Selinexor
Breakdown of trials Basem William, MD has run
Lymphoma
Acute Myeloid Leukemia
Preleukemia
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Basem William, MD specialize in?
Basem William, MD focuses on Lymphoma and Acute Myeloid Leukemia. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are undergoing treatment.
Is Basem William, MD currently recruiting for clinical trials?
Yes, Basem William, MD is currently recruiting for 2 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Basem William, MD has studied deeply?
Yes, Basem William, MD has studied treatments such as NEXI-001 T cell product, Ibrutinib, AB-101.
What is the best way to schedule an appointment with Basem William, MD?
Apply for one of the trials that Basem William, MD is conducting.
What is the office address of Basem William, MD?
The office of Basem William, MD is located at: OhioHealth Research Institute, Columbus, Ohio 43214 United States. This is the address for their practice at the OhioHealth Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.